Hence, we performed a systematic review and meta-analysis of comparative studies to determine the impact of EGFR sensitizing mutations on tumour overall response rates, locoregional and distant disease recurrence rates, recurrence-free and overall survival as well as toxicity outcomes in patients with non-metastatic lung adenocarcinoma treated with definitive TRT with or without chemotherapy. Here, EGFR is linked to neoplasm.